Amusa Sarafadeen Adebayo

Dr. Amusa Sarafadeen Adebayo

Pharmaceutical Sciences, Howard University, Washington, District of Columbia, USA
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AAAmusa Sarafadeen Adebayo
Amusa Sarafadeen Adebayo
KAKafilat Agbaje
Kafilat Agbaje
SASimeon K. Adesina
Simeon K. Adesina
OOOluwabukunmi Olajubutu
Oluwabukunmi Olajubutu
Colorectal cancer (CRC) is one of the deadliest malignancies in the US, ranking fourth after lung, prostate, and breast cancers, respectively, in general populations. It continues to be a menace, and the incidence has been projected to more than double by 2035, especially in underdeveloped countries. This review seeks to provide some insights into the disease progression, currently available treatment options and their challenges, and future perspectives. Searches were conducted in the PubMed search engine in the university’s online library. The keywords were “Colorectal Cancer” AND “disease process” OR “disease mechanisms” OR “Current Treatment” OR “Prospects”. Selection criteria were original articles published primarily during the period of 2013 through 2023. Abstracts, books and documents, and reviews/systematic reviews were filtered out. Of over 490 thousand articles returned, only about 800 met preliminary selection criteria, 200 were reviewed in detail, but 191 met final selection criteria. Fifty-one other articles were used due to cross-referencing. Although recently considered a disease of lifestyle, CRC incidence appears to be rising in countries with low, low–medium, and medium social demographic indices. CRC can affect all parts of the colon and rectum but is more fatal with poor disease outcomes when it is right-sided. The disease progression usually takes between 7–10 years and can be asymptomatic, making early detection and diagnosis difficult. The CRC tumor microenvironment is made up of different types of cells interacting with each other to promote the growth and proliferation of the tumor cells. Significant advancement has been made in the treatment of colorectal cancer. Notable approaches include surgery, chemotherapy, radiation therapy, and cryotherapy. Chemotherapy, including 5-fluorouracil, irinotecan, oxaliplatin, and leucovorin, plays a significant role in the management of CRC that has been diagnosed at advanced stages. Two classes of monoclonal antibody therapies have been approved by the FDA for the treatment of colorectal cancer: the vascular endothelial growth factor (VEGF) inhibitor, e.g., bevacizumab (Avastin®), and the epidermal growth factor receptor (EGFR) inhibitor, e.g., cetuximab (Erbitux®) and panitumumab (Verbitix®). However, many significant problems are still being experienced with these treatments, mainly off-target effects, toxic side effects, and the associated therapeutic failures of small molecular drugs and the rapid loss of efficacy of mAb therapies. Other novel delivery strategies continue to be investigated, including ligand-based targeting of CRC cells.

22 April 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
OOOluwabukunmi Olajubutu
Oluwabukunmi Olajubutu
OGOmotola Deborah Gbadegesin
Omotola Deborah Gbadegesin
AAAmusa Sarafadeen Adebayo
Amusa Sarafadeen Adebayo
SASimeon K. Adesina
Simeon K. Adesina
Pancreatic cancer is fast becoming a global menace and it is projected to be the second leading cause of cancer-related death by 2030. Pancreatic adenocarcinomas, which develop in the pancreas’ exocrine region, are the predominant type of pancreatic cancer, representing about 95% of total pancreatic tumors. The malignancy progresses asymptomatically, making early diagnosis difficult. It is characterized by excessive production of fibrotic stroma known as desmoplasia, which aids tumor growth and metastatic spread by remodeling the extracellular matrix and releasing tumor growth factors. For decades, immense efforts have been harnessed toward developing more effective drug delivery systems for pancreatic cancer treatment leveraging nanotechnology, immunotherapy, drug conjugates, and combinations of these approaches. However, despite the reported preclinical success of these approaches, no substantial progress has been made clinically and the prognosis for pancreatic cancer is worsening. This review provides insights into challenges associated with the delivery of therapeutics for pancreatic cancer treatment and discusses drug delivery strategies to minimize adverse effects associated with current chemotherapy options and to improve the efficiency of drug treatment.

1 January 2012 in journal of Pharmaceutical Technology and Drug Research
Verified
Journal Article
Open access
PDF file
JSJankie Satish
Jankie Satish
AAAmusa Sarafadeen Adebayo
Amusa Sarafadeen Adebayo
PGPillai Gopalakrishna
Pillai Gopalakrishna
Background: Recent findings suggest bacteria's ability to adapt to various classes of antibiotics through three distinct resistance mechanisms: lipopolysaccharide modification, increased drug efflux, and

5 July 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
AAAdebisi Abiodun Adeleke
Adebisi Abiodun Adeleke
AAAmusa Sarafadeen Adebayo
Amusa Sarafadeen Adebayo
KAKafilat Agbaje
Kafilat Agbaje
OOOluwabukunmi Olajubutu
Oluwabukunmi Olajubutu
SASimeon K. Adesina
Simeon K. Adesina
Colorectal cancer (CRC) is ranked as the third most lethal of all cancers in the USA, following prostate and lung malignancy in men, and breast and lung malignancy in women, respectively. The risk factors for developing colorectal cancer fall into two categories: modifiable risk factors (obesity and physical inactivity, diet, smoking, alcohol, medications, diabetes, and insulin resistance) and non-modifiable risk factors (race and ethnicity, sex, age, and inflammatory bowel disease). The standard therapeutic approaches to the treatment of colorectal cancer have led to a reduction in the burden of colorectal cancer in the USA, with national statistics revealing a reduction in both the incidence and death rates. At the same time, five-year survival rates have also greatly improved. However, associated with these standard treatments are complications, which have become a burden (physical and emotional, financial, and economic burdens, and disability-adjusted life years), affecting the quality of life of CRC patients. This paper discusses the standard therapeutic approaches to managing colorectal cancer, the associated complications, and their management. In addition, a summary of the newly introduced therapeutic approaches for treating CRC, reported improvement in effectiveness over existing strategies and corresponding reduction in therapeutic complications will be discussed.

1 January 2017 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
AOADENIKE OKUNLOLA
ADENIKE OKUNLOLA
AAAmusa Sarafadeen Adebayo
Amusa Sarafadeen Adebayo
MAMoji Christianah Adeyeye
Moji Christianah Adeyeye

14 July 2024 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
Tayo Alex AdekiyaTayo Alex Adekiya
Tayo Alex Adekiya
THTamaro Hudson
Tamaro Hudson
OBOladapo Bakare
Oladapo Bakare
EAEdmund E. Ameyaw
Edmund E. Ameyaw
AAAmusa Sarafadeen Adebayo
Amusa Sarafadeen Adebayo
SASimeon K. Adesina
Simeon K. Adesina
Active targeting to cancer involves exploiting specific interactions between receptors on the surface of cancer cells and targeting moieties conjugated to the surface of vectors such that site-specific delivery is achieved. Prostate specific membrane antigen (PSMA) has proved to be an excellent target for active targeting to prostate cancer. We report the synthesis and use of a PSMA-specific ligand (Glu-NH-CO-NH-Lys) for the site-specific delivery of brusatol- and docetaxel-loaded poly(lactide-co-glycolide) (PLGA) nanoparticles to prostate cancer. The PSMA targeting ligand covalently linked to PLGA-PEG3400 was blended with methoxyPEG-PLGA to prepare brusatol- and docetaxel-loaded nanoparticles with different surface densities of the targeting ligand. Flow cytometry was used to evaluate the impact of different surface densities of the PSMA targeting ligand in LNCaP prostate cancer cells at 15 min and 2 h. Cytotoxicity evaluations of the targeted nanoparticles reveal differences based on PSMA expression in PC-3 and LNCaP cells. In addition, levels of reactive oxygen species (ROS) were measured using the fluorescent indicator, H2DCFDA, by flow cytometry. PSMA-targeted nanoparticles loaded with docetaxel and brusatol showed increased ROS generation in LNCaP cells compared to PC-3 at different time points. Furthermore, the targeted nanoparticles were evaluated in male athymic BALB/c mice implanted with PSMA-producing LNCaP cell tumors. Evaluation of the percent relative tumor volume show that brusatol-containing nanoparticles show great promise in inhibiting tumor growth. Our data also suggest that the dual drug-loaded targeted nanoparticle platform improves the efficacy of docetaxel in male athymic BALB/c mice implanted with PSMA-producing LNCaP cell tumors.